Ypsomed is building its first production site in the USA in Holly Springs (Wake County, North Carolina) and is investing around CHF 200 million in the first phase. Products for the US market are to be delivered from there from the end of 2027.
The company acquires an existing building with 15,000 square metres of space and the option to expand at a later date for the expansion. Around 100 jobs will be created in the start-up phase, with plans to expand to around 200 employees in the medium term. Ypsomed justifies the move with the proximity to customers and the strengthening of global partnerships.
Site selection and schedule
Holly Springs is located in North Carolina's Research Triangle, which is home to over 650 life sciences companies along the biopharmaceutical value chain. According to the city, Ypsomed complements the local ecosystem by manufacturing devices needed to produce life-saving medicines. Supply to the US market is planned from the end of 2027.
Capacities and employment
The start will take place in an existing building, which, according to the company, will enable rapid installations and subsequent expansions. Depending on demand, the workforce is expected to grow from around 100 to around 200 employees initially.
Classification in the expansion strategy
At the same time, Ypsomed is pushing ahead with capacity expansion in other regions: the first own plant in Changzhou, China, was launched in 2025; In Germany, the expansion of the „Schwerin 2“ site has begun. In Switzerland, around CHF 200 million is being invested in the Solothurn site; the Burgdorf-Lochbach production site was modernised and expanded in 2023. These measures are intended to meet the growing global demand for injection systems for self-medication.
Source: Ypsomed
